Literature DB >> 7529348

Effects of L-arginine and L-nitro-arginine methyl ester on recovery of neonatal lamb hearts after cold ischemia. Evidence for an important role of endothelial production of nitric oxide.

T Hiramatsu1, J M Forbess, T Miura, J E Mayer.   

Abstract

Myocardial ischemia and reperfusion results in both ventricular and endothelial dysfunction. We have found that the endothelial defect is a reduced vasodilator response to an intraarterial infusion of acetylcholine that is likely due to reduced nitric oxide release, and we have hypothesized that reduced endothelial nitric oxide production contributes to postischemic cardiac dysfunction. However, others report that nitric oxide is deleterious after ischemia. We therefore examined the effects of infusions of L-arginine (3 mmol/L), a precursor of nitric oxide, D-arginine (3 mmol/L), an inactive stereoisomer of L-arginine, L-nitro-arginine methyl ester (1 mmol/L); a competitive inhibitor of nitric oxide synthase, and L-nitro-arginine methyl ester (1 mmol/L) plus L-arginine (3 mmol/L) versus controls in isolated blood-perfused neonatal lamb hearts having 2 hours of cold cardioplegic ischemia. L-nitro-arginine methyl ester was given before reperfusion, and L-arginine and D-arginine were infused for the first 20 minutes of postischemic reperfusion. At 30 minutes of reperfusion, by comparison with the control group, the L-arginine group showed significantly better recovery (p < 0.05) of left ventricular systolic function (maximum developed pressure, developed pressure at V10 [balloon volume to produce an end-diastolic pressure of 10 mm Hg during baseline measurement], positive maximum dP/dt, and dP/dt at V10), diastolic function (negative maximum dP/dt), coronary blood flow, and endothelial function assessed by the coronary vascular resistance response to acetylcholine. The L-nitro-arginine methyl ester hearts showed a significantly poorer recovery (p < 0.05) in left ventricular function, coronary blood flow, and endothelial function than the control group. These effects of L-nitro-arginine methyl ester were reversed to equal control values by adding a 3 mmol/L concentration of L-arginine to L-nitro-arginine methyl ester. There were no significant differences in the recovery of any variables between the D-arginine and control groups. These results point to an important salutary role for the endothelial production of nitric oxide in cardiac recovery after hypothermic ischemia in neonatal lamb hearts. The mechanism of these beneficial effects of L-arginine after ischemia and reperfusion is likely due to enhancement of the endothelial production of nitric oxide.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7529348     DOI: 10.1016/S0022-5223(95)70423-X

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Inhibition of nitric oxide synthesis improves left ventricular contractility in neonatal pigs late after cardiopulmonary bypass.

Authors:  R R Chaturvedi; V E Hjortdal; E V Stenbog; H B Ravn; P White; T D Christensen; A B Thomsen; J Pedersen; K E Sorensen; A N Redington
Journal:  Heart       Date:  1999-12       Impact factor: 5.994

2.  Role of nitric oxide in regulating cardiac electrophysiology.

Authors:  L Wang
Journal:  Exp Clin Cardiol       Date:  2001

3.  Nitric oxide donor, NOC7, reveals dose dependently and cGMP pathway independently biphasic effects on contractile force of isolated rat heart after global ischemia.

Authors:  Ling Liu; Hui Yue; Bing Guo; Xin He; Jing Wang; Jin-Cheng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

4.  Nitric oxide donor, NOC7, reveals biphasic effect on contractile force of isolated rat heart after global ischemia.

Authors:  Yue Hui; Toshiaki Mochizuki; Kazunao Kondo; Kazuo Umemura; Shigehito Sato
Journal:  J Anesth       Date:  2008-08-07       Impact factor: 2.078

Review 5.  The role of nitric oxide in cardiac surgery.

Authors:  Y Nonami
Journal:  Surg Today       Date:  1997       Impact factor: 2.540

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.